Credit Suisse Group upgraded shares of Quest Diagnostics (NYSE:DGX) from a neutral rating to an outperform rating in a research note published on Tuesday, MarketBeat Ratings reports. Credit Suisse Group currently has $107.00 price objective on the medical research company’s stock.

Several other research firms have also issued reports on DGX. Goldman Sachs Group began coverage on shares of Quest Diagnostics in a report on Monday, January 29th. They set a buy rating and a $117.00 price target for the company. Mizuho set a $113.00 price target on shares of Quest Diagnostics and gave the stock a buy rating in a report on Wednesday, January 24th. Piper Jaffray Companies restated a hold rating and set a $110.00 price target on shares of Quest Diagnostics in a report on Thursday, February 1st. Canaccord Genuity restated a buy rating and set a $110.00 price target on shares of Quest Diagnostics in a report on Tuesday, January 16th. Finally, Zacks Investment Research upgraded shares of Quest Diagnostics from a hold rating to a buy rating and set a $115.00 price target for the company in a report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $107.40.

Quest Diagnostics (DGX) opened at $101.39 on Tuesday. The stock has a market cap of $13,503.18, a P/E ratio of 17.53, a P/E/G ratio of 1.78 and a beta of 0.67. Quest Diagnostics has a fifty-two week low of $90.10 and a fifty-two week high of $112.96. The company has a quick ratio of 1.15, a current ratio of 1.24 and a debt-to-equity ratio of 0.76.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. Quest Diagnostics had a net margin of 10.00% and a return on equity of 15.41%. The firm’s quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the business earned $1.31 EPS. equities analysts expect that Quest Diagnostics will post 6.59 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 18th. Stockholders of record on Wednesday, April 4th will be given a dividend of $0.50 per share. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.45. The ex-dividend date is Tuesday, April 3rd. This represents a $2.00 annualized dividend and a dividend yield of 1.97%. Quest Diagnostics’s dividend payout ratio (DPR) is 32.73%.

In other news, SVP Catherine T. Doherty sold 21,294 shares of the firm’s stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $104.00, for a total transaction of $2,214,576.00. Following the completion of the sale, the senior vice president now owns 90,709 shares of the company’s stock, valued at approximately $9,433,736. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP J. E. Davis sold 63,880 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $98.68, for a total transaction of $6,303,678.40. Following the sale, the executive vice president now directly owns 101,423 shares of the company’s stock, valued at approximately $10,008,421.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 192,014 shares of company stock valued at $19,950,134. Insiders own 1.75% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. APG Asset Management N.V. grew its position in Quest Diagnostics by 156.0% in the 3rd quarter. APG Asset Management N.V. now owns 2,683,901 shares of the medical research company’s stock valued at $251,320,000 after purchasing an additional 1,635,700 shares during the period. Rockefeller Financial Services Inc. grew its position in Quest Diagnostics by 741,981.0% in the 4th quarter. Rockefeller Financial Services Inc. now owns 1,246,696 shares of the medical research company’s stock valued at $122,787,000 after purchasing an additional 1,246,528 shares during the period. Bessemer Group Inc. grew its position in Quest Diagnostics by 73.1% in the 4th quarter. Bessemer Group Inc. now owns 2,107,796 shares of the medical research company’s stock valued at $207,596,000 after purchasing an additional 889,802 shares during the period. Victory Capital Management Inc. grew its position in Quest Diagnostics by 29.1% in the 4th quarter. Victory Capital Management Inc. now owns 2,487,295 shares of the medical research company’s stock valued at $244,974,000 after purchasing an additional 560,538 shares during the period. Finally, Janus Henderson Group PLC grew its position in Quest Diagnostics by 24.1% in the 3rd quarter. Janus Henderson Group PLC now owns 1,801,477 shares of the medical research company’s stock valued at $168,690,000 after purchasing an additional 349,703 shares during the period. 90.22% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://theolympiareport.com/2018/02/14/quest-diagnostics-dgx-stock-rating-upgraded-by-credit-suisse-group.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.